hMPV Vaccine

About Phylex BioSciences

Phylex BioSciences is a private, pre-clinical stage biotech leveraging advanced AI and deep learning to design next-generation mRNA nanoparticle vaccines. Its core technology platform aims to overcome limitations of current vaccines, such as immune imprinting and short-lived immunity, by encoding for highly immunogenic nanoparticles. The company's pipeline targets high-fatality and emerging viruses like Nipah, SARS-CoV-2, Chikungunya, West Nile, and human metapneumovirus, positioning it in the growing field of proactive pandemic preparedness.

About Vironovative

ViroNovative is a private, pre-revenue biotech firm with a singular focus on addressing the unmet medical need posed by human Metapneumovirus (hMPV). Its strategy is built on owning and licensing core patents related to the virus, discovered at Erasmus MC in 2001, and co-developing a full spectrum of countermeasures—from diagnostics to therapeutics—with industrial partners. Led by a seasoned entrepreneur and closely tied to leading academic virology research, the company aims to generate economic value through its extensive IP portfolio and partnership model rather than internal late-stage development.

Therapeutic Areas